The underlying mechanism and targeted therapy strategy of miRNAs cross-regulating EMT process through multiple signaling pathways in hepatocellular carcinoma

Front Mol Biosci. 2024 Mar 22:11:1378386. doi: 10.3389/fmolb.2024.1378386. eCollection 2024.

Abstract

The consistent notion holds that hepatocellular carcinoma (HCC) initiation, progression, and clinical treatment failure treatment failure are affected by the accumulation of various genetic and epigenetic alterations. MicroRNAs (miRNAs) play an irreplaceable role in a variety of physiological and pathological states. meanwhile, epithelial-mesenchymal transition (EMT) is a crucial biological process that controls the development of HCC. miRNAs regulate the intermediation state of EMTor mesenchymal-epithelial transition (MTE)thereby regulating HCC progression. Notably, miRNAs regulate key HCC-related molecular pathways, including the Wnt/β-catenin pathway, PTEN/PI3K/AKT pathway, TGF-β pathway, and RAS/MAPK pathway. Therefore, we comprehensively reviewed how miRNAs produce EMT effects by multiple signaling pathways and their potential significance in the pathogenesis and treatment response of HCC. emphasizing their molecular pathways and progression in HCC initiation. Additionally, we also pay attention to regulatory mechanisms that are partially independent of signaling pathways. Finally, we summarize and propose miRNA-targeted therapy and diagnosis and defense strategies forHCC. The identification of the mechanism leading to the activation of EMT programs during HCC disease processes also provides a new protocol for the plasticity of distinct cellular phenotypes and possible therapeutic interventions. Consequently, we summarize the latest progress in this direction, with a promising path for further insight into this fast-moving field.

Keywords: EMT; HCC; miRNA; signaling pathway; targeted therapy.

Publication types

  • Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The study was funded by the molecular pathology research project of atrophic gastritis in chongqing Medical University, project number BYKY-CX2023018; chongqing Medical University Innovative Team Atrophic Gastritis Outcome Mechanism and Standardized Diagnosis and Treatment project funding, project number W0183; Chongqing Municipal Education Commission GAMT (guanidinoacetic acid N-methyltransferase) enhances the stemness of tumor stem cells through metabolic reprogramming to promote the mechanism of colorectal cancer progression funded research project, project number KJQN202200463.